Journal of Clinical Endocrinology & Metabolism, Vol 66, 39-45, Copyright © 1988 by Endocrine Society

ARTICLES

Differential effects of somatostatin (SRIH) and a SRIH analog, SMS 201- 995, on the secretion of growth hormone and thyroid-stimulating hormone in man

TC Williams, M Kelijman, WC Crelin, TR Downs and LA Frohman
Department of Internal Medicine, University of Cincinnati, College of Medicine, Ohio 45267.

We compared the ability of SRIH and SRIH analog, SMS 201-995 (SMS), to inhibit stimulated GH and TSH secretion in men who received 120-min iv infusions of saline, SRIH (5, 50, and 500 micrograms/h), and SMS (3, 30, and 300 ng/kg.h) together with a bolus iv injection of GHRH (1 microgram/kg) and TRH (500 micrograms). Integrated GH secretion during the 60 min after GHRH plus TRH injection was decreased compared to that after saline by (mean +/- SE) 32 +/- 14% (P = 0.059), 78 +/- 5% (P less than 0.001), and 88 +/- 3% (P less than 0.001) during the 5, 50, and 500 micrograms/h SRIH infusions, and by 13 +/- 7% (P = NS), 50 +/- 15% (P less than 0.05), and 80 +/- 6% (P less than 0.001) during the 3, 30, and 300 ng/kg.h SMS infusions. In contrast, integrated TSH secretion was unaltered during the 5 micrograms/h SRIH and 3 ng/kg.h SMS infusions; it decreased by only 43 +/- 5% (P less than 0.001) and 66 +/- 4% (P less than 0.001) during the 50 and 500 micrograms/h SRIH infusions and by 33 +/- 8% (P less than 0.05) and 50 +/- 3% (P less than 0.001) during the 30 and 300 ng/kg.h SMS infusions. Analysis of the dose-response curves indicated approximately 10- and 5-fold greater potencies of SRIH and SMS, respectively, in inhibiting GH as compared to TSH secretion. These results quantify the effect of SRIH as an inhibitor of GH secretion and suggest that if SRIH has a physiological role in the inhibition of TSH secretion in man, it is limited to conditions associated with marked suppression of GH.

This article has been cited by other articles:

				E. V. Dimaraki, C. A. Jaffe, C. Y. Bowers, P. Marbach, and A. L. Barkan Pulsatile and nocturnal growth hormone secretions in men do not require periodic declines of somatostatin Am J Physiol Endocrinol Metab, July 1, 2003; 285(1): E163 - E170. [Abstract] [Full Text] [PDF]

				R. Nass, S. S. Pezzoli, I. M. Chapman, J. Patrie, R. L. Hintz, M. L. Hartman, and M. O. Thorner IGF-I does not affect the net increase in GH release in response to arginine Am J Physiol Endocrinol Metab, October 1, 2002; 283(4): E702 - E710. [Abstract] [Full Text] [PDF]

				E. V. Dimaraki, C. A. Jaffe, R. Demott-Friberg, M. Russell-Aulet, C. Y. Bowers, P. Marbach, and A. L. Barkan Generation of growth hormone pulsatility in women: evidence against somatostatin withdrawal as pulse initiator Am J Physiol Endocrinol Metab, March 1, 2001; 280(3): E489 - E495. [Abstract] [Full Text] [PDF]

				I. M. Chapman, M. L. Hartman, K. S. Pieper, E. H. Skiles, S. S. Pezzoli, R. L. Hintz, and M. O. Thorner Recovery of Growth Hormone Release from Suppression by Exogenous Insulin-Like Growth Factor I (IGF-I): Evidence for a Suppressive Action of Free Rather Than Bound IGF-I J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2836 - 2842. [Abstract] [Full Text]

				I. Yang, S. Park, J. Woo, S. Kim, J. Kim, Y. Kim, and Y. Choi Growth Hormone Response to the Hypothalamic Somatostatinergic Activity in Acromegalic Patients J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2492 - 2496. [Abstract] [Full Text] [PDF]